All In Biotech

BLA 103979 · Genzyme

Fabrazyme

Agalsidase Beta · Intravenous · Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme

NovelAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Jul 10, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2003

Apr 24, 2003

Approved uses

5

Original approval plus efficacy supplements

Registered trials

25

8 Phase 3, 1 recruiting

FAERS reports

9,357

4,797 serious, 703 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. Initiate FABRAZYME in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue FABRAZYME and immediately initiate appropriate medical treatment, including use of epinephrine. Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis and to seek immediate medical care should symptoms occur. [see Warnings and Precautions (5.1) ] . WARNING: HYPERSENSITIVITY REACTIONS INCLUDING...

What it is approved for

From the label in effect Aug 22, 2025.

FABRAZYME ® is indicated for the treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease. FABRAZYME is a hydrolytic lysosomal neutral glycosphingolipid-specific enzyme indicated for the treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease. ( 1 )

Mechanism: FABRAZYME (agalsidase beta) provides an exogenous source of α-galactosidase A in Fabry disease patients. Agalsidase beta is internalized and transported into lysosomes where it exerts enzymatic activity and reduces accumulated GL-3.

Therapeutic areas: Cardiovascular and metabolic · Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 11, 2021 Supplement 5309 · Efficacy OrphanLetterLabelReview
  • Sep 29, 2006 Supplement 5066 · Efficacy OrphanLetterLabel
  • Sep 29, 2006 Supplement 5058 · Efficacy OrphanLetterLabel
  • Sep 29, 2006 Supplement 5065 · Efficacy OrphanLabelLetter
  • Apr 24, 2003 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLetterLabelReview
2 products under this application
  • FABRAZYME · AGALSIDASE BETA 35MG/VIAL · VIAL, INTRAVENOUS · Prescription
  • FABRAZYME · AGALSIDASE BETA 5MG/VIAL · VIAL, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Agalsidase Beta" as an intervention, any sponsor and status, largest first.

All 25 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pyrexia526
  • pain514
  • malaise497
  • chills481
  • nausea477
  • fatigue433
  • dyspnoea428
  • headache382
  • vomiting378
  • weight decreased350
  • pain in extremity321
  • infusion related reaction301

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004259
2005312
2006197
2007169
2008181
2009170
2010187
2011193
2012175
2013313
2014782
2015590
2016473
2017588
2018508
2019468
2020331
2021480
2022630
2023642
2024619
2025575
2026515

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Fabrazyme (Agalsidase Beta)

2024 spending

$41.3M

Beneficiaries

110

2,032 claims

Per beneficiary

$375,136

$4,731.35 per unit

View as table
YearSpending
2020$29,364,445
2021$33,112,272
2022$37,333,578
2023$39,532,208
2024$41,264,991

Part B: Fabrazyme (Agalsidase Beta) · HCPCS J0180

2024 spending

$66.3M

Beneficiaries

203

3,596 claims

Per beneficiary

$326,823

2024 ASP limit $220.77 per unit

View as table
YearSpending
2020$50,489,089
2021$52,527,145
2022$62,283,822
2023$66,506,215
2024$66,345,021

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 49 on PubMed

Sponsor: Sanofi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.